Phosphagenics solves oxycodone patch design problems and plans for new trial
Phosphagenics (ASX:POH) has solved the crystallisation problems with its oxycodone patch and is aiming to re-enter the clinic by the end of this quarter.
Phosphagenics (ASX:POH, OTCQX:PPGNY) is planning to take its oxycodone pain patch back into the clinic by the end of this quarter after design flaws were resolved.
The company had German drug development company tesa Labtec GmbH work on resolving crystallisation issues that were experienced with the original design.
Crystallisation is an issue because it potentially allows the oxycodone extracted and misused. Resolving these issues are key to seeing it approved by regulators.
tesa Labtec has experience in opioid patch development and specialises in self-adhesive products for a variety of purposes.
Phosphagenics now intends to take its TPM (targeted penetration matrix) patch with oxycodone to clinical trials before the end of the first quarter of this year, and will continue trials of its oxymorphone patch.
“Together these opioid candidates represent the implementation of the company’s strategy to leverage the powerful TPM platform delivery technology to develop a range of innovative transdermal products that are capable of managing all levels of chronic pain,” said CEO Dr Esra Ogru.
Phosphagenics (ASX:POH) was up 7% to 15.5c in morning trading today.
Stevia leaf extract has potential as an anticancer treatment
When fermented with bacteria isolated from banana leaves, stevia extract kills off pancreatic...
Even non-antibiotics can disrupt the microbiome
Many non-antibiotics inhibit useful gut bacteria, giving rise to an imbalance in the microbiome,...
How brain stem cells move between resting and active states
Understanding this process is crucial, because it underpins how the brain repairs itself and...
